AstraZeneca moves quickly to shed another noncore drug in ProStrakan deal

U.K. multinational AstraZeneca ($AZN) announced a second deal in Asia in as many days to sell a non-core drug, fetching $70 million from a unit of Tokyo-based Kyowa Hakko Kirin. The latest deal sees ProStrakan, based in Galashiels, Scotland, buy European rights to Moventig, a drug that treats opioid-induced constipation, AstraZeneca said in a press release. ProStrakan will also pay AstraZeneca unspecified tiered double-digit royalties and potential milestones. On Monday, the company announced a deal with third-party distributor China Medical Systems Holding for rights to two cardio drugs that garnered $500 million. The effort by AstraZeneca to shed noncore drugs is aimed at building cash pile for pipeline products that hold blockbuster promise. Release

Suggested Articles

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

Hoping to expand its hospital portfolio in Japan, the Novartis generics unit is buying Aspen Pharmacare's operations there for up to €400 million.

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.